Aurora Kinase B (AURKB), the target by which fostamatinib was identified as a drug of potential benefit for AD + P, has recently been shown to play a role in promoting neurite formation during early neuronal development27 and to promote axonal repair after injury in post-mitotic neurons28. This evidence concerns the gene AURKB and Alzheimer disease.